The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III clinical trial of sequential capecitabine or 5-FU plus bevacizumab (Cape/5-FU+Bmab) followed by Cape/5-FU plus oxaliplatin plus Bmab (CapeOX/mFOLFOX6+Bmab) versus combination CapeOX/mFOLFOX6+Bmab in advanced colorectal cancer: The C-cubed (C3) study.
 
Mototsugu Shimokawa
No Relationships to Disclose
Concurrent Hormonal Therapy and Vinorelbine in First Line Treatment of Advanced Breast Cancer. Preliminary Results.
 
Hitoshi Ojima
Honoraria - Chugai Pharma; Merck; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Hideyuki Mishima
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
 
Akira Sawaki
Honoraria - Bayer; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
 
Takeshi Nagasaka
No Relationships to Disclose
 
Michio Inukai
No Relationships to Disclose
 
Katsunori Shinozaki
Honoraria - Asahi Kasei; Chugai Pharma; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Hiroaki Tanioka
No Relationships to Disclose
 
Junichiro Nasu
No Relationships to Disclose
 
Tomohiro Nishina
Honoraria - EMD Serono
Research Funding - Chugai Pharma
 
Shoichi Hazama
Research Funding - NEC Corporation of America; Toyo Kohan Co., Ltd.
 
Masazumi Okajima
No Relationships to Disclose
 
Akihito Tsuji
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yasushi Tsuji
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Medicon; Merck Serono; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshinori Munemoto
No Relationships to Disclose
 
Shigeki Yamaguchi
No Relationships to Disclose
 
Yoshiyuki Yamaguchi
Employment - Taiho Pharmaceutical (I)
Honoraria - Chugai Pharma; Ono Pharmaceutical
Research Funding - Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Kobayashi Pharmaceutical (Inst); Kobayashi Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst)